



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021, please refer to the [EMA](#) website.

Credelio Plus 56.25 mg/2.11 mg Chewable Tablets for Dogs (1.4 kg - 2.8 kg) Vm 52127/5033

•	23 February 2023	Addition of a new indication: For the treatment of demodicosis.
•	31 May 2022	Change(s) in the manufacturing process of the active substance.
•	19 November 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
•	21 October 2021	Extension of the shelf-life of an excipient.
•	28 June 2021	<p>Addition of a manufacturer of a starting material. Changes in the specification parameters of a starting material. Change in the manufacturer of a starting material.</p> <p>Change in the manufacturer of a starting material used in the manufacturing process of the active where no Ph. Eur. Certificate of Suitability is part of the approved dossier.</p> <p>Addition of a manufacturer of a starting material. Changes in the specification parameters of a starting material. Change in the manufacturer of a starting material.</p> <p>Addition of a manufacturer of a starting material. Changes in the specification parameters of a starting material. Change in the manufacturer of a starting material.</p> <p>Addition of a manufacturer of a starting material. Changes in the specification parameters of a starting material. Change in the manufacturer of a starting material.</p> <p>Change in the name of a manufacturer of a starting material used in the manufacturing process of the active substance.</p> <p>Change in the address of a manufacturer of a starting material used in the manufacturing process of the active substance.</p> <p>Minor change in the manufacturing process of the active substance.</p> <p>Minor change in the manufacturing process of the active substance.</p> <p>Deletion of manufacturing site for an active substance manufacturer responsible for the supply of a starting material.</p>